Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial productsBolsters and diversifies Ligand’s ...
Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category of antivirals engineered to target shared viral ...
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por ...
Dr. Georg Winter explores how chemical neomorphs can give proteins new functions by reshaping their cellular interactions, ...
Arecor Therapeutics PLC (AIM:AREC), the Cambridge-based diabetes biotech, says positive negotiations are underway on a broader co-development and commercialisation partnership for its lead insulin ...
Madison have reported a new approach to forming carbon-nitrogen bonds, a critical step in the synthesis of amines widely used ...
Researchers have developed a chemoproteomics method using silyl ether chemistry to improve detection of small-molecule binding sites across the proteome. The approach enhances sensitivity, specificity ...
Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular "keyhole," in the TRPM3 ion channel, ...
Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...
The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results